Organon Expects 2028 ‘Tidal Wave’ For Biosimilars
Firm’s Opdivo And Keytruda Rivals Will Follow Denosumab And Pertuzumab In Coming Years
Organon CEO Kevin Ali provided a detailed overview of the firm’s biosimilars strategy at the J.P. Morgan Healthcare Conference last week, looking ahead to competition on Opdivo and Keytruda in 2028; highlighting nearer-term launches of denosumab and pertuzumab; and providing a breakdown of the firm’s experiences in the competitive US adalimumab market.
